Impacts of dose titration on logistic exposure-response in simulated flexible-dose clinical trials Poster Impacts of dose titration on logistic exposure-response in simulated flexible-dose clinical trials Certara2024年11月22日
Simultaneous Population PKPD Analysis of Belantamab Mafodotin, Soluble BCMA, and Serum M-Protein in Subjects With Relapsed/Refractory Multiple Myeloma Poster Simultaneous Population PKPD Analysis of Belantamab Mafodotin, Soluble BCMA, and Serum M-Protein in Subjects With Relapsed/Refractory Multiple Myeloma Certara2024年11月22日
A Pharmacokinetic Analysis of Drug Concentration Using a Novel Deep Learning Model Poster A Pharmacokinetic Analysis of Drug Concentration Using a Novel Deep Learning Model Certara2024年11月22日
Automatic differentiation, a possible solution to numerical instability in Population PK parameter estimation Poster Automatic differentiation, a possible solution to numerical instability in Population PK parameter estimation Certara2024年11月22日
Building Automated Pharmacometrics Analysis Workflows in R with NMsim Poster Building Automated Pharmacometrics Analysis Workflows in R with NMsim Certara2024年11月22日
Population K-PD Modeling of Plozasiran (ARO-APOC3), a GalNAc-siRNA Conjugate, for the Potential Treatment of Atherosclerotic Cardiovascular Disease (ASCVD) in Patients with Mixed Hyperlipidemia Poster Population K-PD Modeling of Plozasiran (ARO-APOC3), a GalNAc-siRNA Conjugate, for the Potential Treatment of Atherosclerotic Cardiovascular Disease (ASCVD) in Patients with Mixed Hyperlipidemia Certara2024年11月22日
Integrated Population Pharmacokinetic Model of Bemnifosbuvir and Metabolites Poster Integrated Population Pharmacokinetic Model of Bemnifosbuvir and Metabolites Certara2024年11月22日
Indirect Exposure-Response Modeling for Transthyretin Amyloid Cardiomyopathy Treated with Acoramidis (AG10) Poster Indirect Exposure-Response Modeling for Transthyretin Amyloid Cardiomyopathy Treated with Acoramidis (AG10) Certara2024年11月22日
Model-Informed Drug Development Framework for the Development and Dose Optimization of Targeted Radiation Therapies Poster モデルを活かした医薬品開発（MIDD）の枠組みによる、標的放射線療法の開発と投与量の最適化 Certara2024年11月22日
Augmented Definitive Screening Design Provides Efficient Phase 1 Selection of CAR T-cell and Lymphodepletion Regimen Poster Augmented Definitive Screening Design Provides Efficient Phase 1 Selection of CAR T-cell and Lymphodepletion Regimen Certara2024年11月22日
